Tag: Hansa Biopharma
Scottish Medicines Consortium recommends Idefirix for highly sensitised kidney transplant patients
Hansa Biopharma recently announced a recommendation by the Scottish Medicines Consortium (SMC) for its “first-in-class” treatment Idefirix (imlifidase) in the desensitisation of highly sensitised adult...
NICE recommends Idefirix in treatment of highly sensitised kidney transplant recipients
Hansa Biopharma has announced a recommendation by the National Institute for Health and Care Excellence (NICE) for its first-in-class treatment Idefirix (imlifidase) in the...
Hansa Biopharma enrols first patient in US pivotal trial of kidney...
Hansa Biopharma recently announced that the first patient has been enrolled in its CONFIDES trial—a US pivotal, open-label, randomised controlled study—at the Columbia University Medical Center...
Hansa Biopharma announces three-year graft survival of 84% after imlifidase treatment...
Hansa Biopharma has announced three-year follow-up data on graft survival rates in crossmatch positive patients who received imlifidase prior to kidney transplantation. As reported...